Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Panza

Showing results (41-50 of 404) with videos related to

Pageof 41
Sort By:
Annals of Neurology|January 13, 2019
Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?Francesco Panza, Madia Lozupone, Davide Seripa, et al.
Expert Opinion on Biological Therapy|July 2, 2014
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?Francesco Panza, Vincenzo Solfrizzi, Bruno P Imbimbo, et al.
Lancet (London, England)|February 3, 2009
N-3 polyunsaturated fatty acids and statins in heart failureVincenzo Solfrizzi, Cristiano Capurso, Gianluigi Vendemiale, et al.
Journal of the American Geriatrics Society|December 15, 2010
Plasma lipid disturbances and cognitive declineVincenza Frisardi, Francesco Panza, Vincenzo Solfrizzi, et al.
Epigenomics|November 17, 2021
Could epigenetics play a role in suicidal behavior in older age?Madia Lozupone, Anita Mollica, Giuseppe Berardino, et al.
Parkinson'S Disease|June 14, 2016
Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's DiseaseAntonio Daniele, Francesco Panza, Antonio Greco, et al.
Journal of the American Geriatrics Society|November 9, 2010
Plasma levels of n-3 polyunsaturated fatty acids and cognitive decline: possible role of depressive symptoms and apolipoprotein E genotypingFrancesco Panza, Vincenza Frisardi, Davide Seripa, et al.
Frontiers of Neurology and Neuroscience|July 28, 2016
Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical TrialsRosanna Tortelli, Davide Seripa, Francesco Panza, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 21, 2015
Measuring pharmacogenetics in special groups: geriatricsDavide Seripa, Francesco Panza, Julia Daragjati, et al.
Ageing Research Reviews|July 6, 2010
Pharmacogenetics of cytochrome P450 (CYP) in the elderlyDavide Seripa, Andrea Pilotto, Francesco Panza, et al.
Pageof 41

Showing results (41-50 of 404) with videos related to

Sort By:
Pageof 41
Annals of Neurology|January 13, 2019
Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?Francesco Panza, Madia Lozupone, Davide Seripa, et al.
Expert Opinion on Biological Therapy|July 2, 2014
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?Francesco Panza, Vincenzo Solfrizzi, Bruno P Imbimbo, et al.
Lancet (London, England)|February 3, 2009
N-3 polyunsaturated fatty acids and statins in heart failureVincenzo Solfrizzi, Cristiano Capurso, Gianluigi Vendemiale, et al.
Journal of the American Geriatrics Society|December 15, 2010
Plasma lipid disturbances and cognitive declineVincenza Frisardi, Francesco Panza, Vincenzo Solfrizzi, et al.
Epigenomics|November 17, 2021
Could epigenetics play a role in suicidal behavior in older age?Madia Lozupone, Anita Mollica, Giuseppe Berardino, et al.
Parkinson'S Disease|June 14, 2016
Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's DiseaseAntonio Daniele, Francesco Panza, Antonio Greco, et al.
Journal of the American Geriatrics Society|November 9, 2010
Plasma levels of n-3 polyunsaturated fatty acids and cognitive decline: possible role of depressive symptoms and apolipoprotein E genotypingFrancesco Panza, Vincenza Frisardi, Davide Seripa, et al.
Frontiers of Neurology and Neuroscience|July 28, 2016
Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical TrialsRosanna Tortelli, Davide Seripa, Francesco Panza, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 21, 2015
Measuring pharmacogenetics in special groups: geriatricsDavide Seripa, Francesco Panza, Julia Daragjati, et al.
Ageing Research Reviews|July 6, 2010
Pharmacogenetics of cytochrome P450 (CYP) in the elderlyDavide Seripa, Andrea Pilotto, Francesco Panza, et al.
Pageof 41